Kyntra Bio, Inc.
KYNB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000921299
No open-market purchases or sales by Kyntra Bio, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $7.54M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Kyntra Bio, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 56 | 30 | −26 |
| SharesConverted for a 1-for-25 split | 1.32M | 1.06M | −258.9K (−19.6%) |
| Value | $10.2M | $5.62M | −$4.60M (−45.0%) |
New holders (4)
Institutions that held Kyntra Bio, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Connective Capital Management, LLC | 15,000 | $79.5K | 0.07% |
| Tower Research Capital LLC (TRC) | 793 | $4.20K | 0.00% |
| The PNC Financial Services Group, Inc. | 40 | $212 | 0.00% |
| Danske Bank A/S | 1 | $5 | 0.00% |
Sold out (30)
Institutions that held Kyntra Bio, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.